Krebs Biochemicals & Industries Ltd. (KREBSBIO): Krebs Biochemicals Share Price Rises 9.35% Today
- July 31, 2026
- Posted by: Harsh Piplani
- Category: News
Krebs Biochemicals Share Price rose 9.35% today, reaching Rs 58 with a market cap of Rs 114.36 crore.
Krebs Biochemicals & Industries Ltd. (KREBSBIO) saw its share price rise by 9.35% today, closing at Rs 58. The stock opened at Rs 54, reached a high of Rs 58, and a low of Rs 52.7 during the trading session. With a market capitalization of Rs 114.36 crore, Krebs Biochemicals has captured investor attention, although the data does not specify a company-specific catalyst for today’s rally.
Krebs Biochemicals & Industries Ltd. (KREBSBIO) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 58 |
| Previous Close | Rs 53.04 |
| Today's Change | +Rs 4.96 (+9.35%) |
| Day Open | Rs 54 |
| Day High | Rs 58 |
| Day Low | Rs 52.7 |
| Current Volume (BSE) | 780 |
| BSE Traded Volume | 780 |
| NSE Traded Volume | 18,176 |
| Combined NSE + BSE Volume | 18,956 |
| Turnover | Rs 0 crore |
| Market Capitalisation | Rs 114.36 crore |
| Market Cap Category | Micro Cap |
Krebs Biochemicals & Industries Ltd. (KREBSBIO) traded at Rs 58. versus the previous close of Rs 53.04, a rise of 9.35%. The stock opened at Rs 54, reached Rs 58, touched Rs 52.7. Reported volume was 780.
Krebs Biochemicals & Industries Ltd. (KREBSBIO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 114.36 crore |
| P/E Ratio | -7.39x |
| P/B Ratio | -0.7x |
| ROE | 0% |
| ROCE | -40.28% |
| EPS | Rs -7.85 |
| Dividend Yield | 0% |
Krebs Biochemicals & Industries Ltd. was valued at a P/E ratio of -7.39x, a P/B ratio of -0.7x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 0% and ROCE of -40.28%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs -7.85, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Krebs Biochemicals, with a market capitalization of Rs 114.36 crore, operates in the Pharmaceuticals & Drugs industry. The company exhibits a negative P/E ratio of -7.39 and a P/B ratio of -0.7, indicating that it is currently operating at a loss. The Return on Equity (ROE) is 0, while the Return on Capital Employed (ROCE) is -40.28, reflecting challenges in generating returns. The Earnings Per Share (EPS) is -7.85, and the dividend yield is 0, further highlighting the company’s financial struggles. Despite these challenges, the company’s book value per share and sector positioning may offer some context for investors evaluating its long-term potential.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | -7.39x |
| Benchmark Median P/E | 24.59x |
| Benchmark Average P/E | 69.36x |
| Benchmark P/E Range | 3.3x to 3,417.8x |
| Company P/B Ratio | -0.7x |
| Benchmark Median P/B | 1.79x |
| Company ROE | 0% |
| Benchmark Median ROE | 9.91% |
| Company ROCE | -40.28% |
| Benchmark Median ROCE | 12.96% |
| Company Market Capitalisation | Rs 114.36 crore |
| Benchmark Median Market Cap | Rs 146.67 crore |
Krebs Biochemicals & Industries Ltd. (KREBSBIO) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a P/E ratio of -7.39x, which is below the benchmark median of 24.59x, a difference of -130.05%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a ROE of 0%, which is below the benchmark median of 9.91%, a difference of -100%. Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a ROCE of -40.28%, which is below the benchmark median of 12.96%, a difference of -410.8%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
Operating within the Healthcare sector and Pharmaceuticals & Drugs industry, Krebs Biochemicals faces a competitive landscape. The company’s P/E ratio of -7.39 is significantly below the industry median of 24.59 and average of 69.36, indicating a challenging position relative to peers. The P/B ratio of -0.7 also falls below the industry median of 1.79. With an ROE of 0 and ROCE of -40.28, Krebs Biochemicals lags behind the industry averages of 9.91 and 12.96, respectively. The company’s market cap of Rs 114.36 crore is below the industry median of Rs 146.67 crore, positioning it as a smaller player in the sector.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,950.66 | 0 | 0.75 | -2.89 | -0.26 |
| Hikal Ltd. | HIKAL | 2,726.18 | 0 | 2.23 | 15.22 | 16.15 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,700.98 | 39.17 | 7.93 | 28.21 | 26.35 |
| Panacea Biotec Ltd. | PANACEABIO | 2,598.26 | 0 | 8.89 | 0 | 5.36 |
| Beta Drugs Ltd. | BETA | 2,475.7 | 58.88 | 9.32 | 18.65 | 22.17 |
Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a P/E ratio of -7.39x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at -40.28% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a market capitalisation of Rs 114.36 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
In comparison to its peers, Krebs Biochemicals exhibits weaker financial metrics. Companies like Hikal Ltd. and Kwality Pharmaceuticals Ltd. show stronger P/B ratios and positive ROE and ROCE figures. For instance, Hikal Ltd. has a P/B of 2.23, ROE of 15.22, and ROCE of 16.15, while Kwality Pharmaceuticals Ltd. boasts a P/E of 39.17, P/B of 7.93, ROE of 28.21, and ROCE of 26.35. These comparisons highlight the competitive challenges Krebs Biochemicals faces within the industry.
Why Investors Are Watching Krebs Biochemicals
Investors are closely watching Krebs Biochemicals due to its recent price rise and market positioning. Key factors include:
- Significant 9.35% share price gain today.
- Weak technical momentum with RSI at 36.12.
- Challenging fundamentals with negative P/E and P/B ratios.
- Competitive sector positioning within Pharmaceuticals & Drugs.
Monitoring future price movements, technical indicators, and sector developments will be crucial for investors considering this stock.
About Krebs Biochemicals
Krebs Biochemicals & Industries Ltd. operates in the Pharmaceuticals & Drugs industry, focusing on the development and manufacturing of biochemicals. The company is involved in producing a range of pharmaceutical products, catering to various healthcare needs. Despite its current financial challenges, Krebs Biochemicals continues to explore opportunities within the healthcare sector, aiming to enhance its market presence and product offerings.
Track Krebs Biochemicals Share Price on Univest
Use Krebs Biochemicals & Industries Ltd. (KREBSBIO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors can track Krebs Biochemicals Share Price on Univest for live updates on share price, technical indicators, fundamental ratios, and market insights. Univest provides comprehensive data to help investors make informed decisions, offering a detailed view of the company’s performance and market trends.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Krebs Biochemicals?
Ans. The current share price of Krebs Biochemicals is Rs 58, reflecting a 9.35% increase from the previous close of Rs 53.04. The stock moved 9.35% during the session. The intraday range extended from Rs 52.7 to Rs 58.
How much did Krebs Biochemicals' share price rise today?
Ans. Krebs Biochemicals' share price rose by 9.35% today, closing at Rs 58, up from the previous close of Rs 53.04. The stock moved 9.35% during the session. The intraday range extended from Rs 52.7 to Rs 58.
What is the market capitalization of Krebs Biochemicals?
Ans. The market capitalization of Krebs Biochemicals is Rs 114.36 crore, categorizing it as a Micro Cap company. The company operates in the Healthcare sector. Its P/E ratio is -7.39x. ROE is 0% and ROCE is -40.28%.
What is the P/E ratio of Krebs Biochemicals?
Ans. Krebs Biochemicals has a negative P/E ratio of -7.39, indicating it is currently operating at a loss. The company trades at a P/E ratio of -7.39x. Its P/B ratio is -0.7x.
How does Krebs Biochemicals' P/B ratio compare to the industry?
Ans. Krebs Biochemicals' P/B ratio of -0.7 is below the industry median of 1.79, indicating a challenging financial position. The company trades at a P/E ratio of -7.39x. Its P/B ratio is -0.7x.
What is the ROCE of Krebs Biochemicals?
Ans. The Return on Capital Employed (ROCE) for Krebs Biochemicals is -40.28, reflecting difficulties in generating returns. ROE stands at 0%. ROCE stands at -40.28%. The relevant peer median ROE is 9.91%.
How does Krebs Biochemicals' market cap compare to its peers?
Ans. Krebs Biochemicals' market cap of Rs 114.36 crore is below the industry median of Rs 146.67 crore, positioning it as a smaller player. The company operates in the Healthcare sector.
